Bigfoot Biomedical, headquartered in Milpitas, provides simple and easy-to-use tools to significantly reduce the cognitive, emotional, and financial burden of insulin-requiring diabetes. Bigfoot is challenging the current approach to diabetes innovation by focusing on simplicity over complexity so people with diabetes can live the lives they choose. One of their key product, the insulin calculation cap, epitomizes their commitment to enhancing the quality of life for diabetes patients by simplifying insulin dosing. Abbott completed the acquisition of Biofoot Biomedical in Sep 2023.